insights_auto
Why is KYNB up २.८५%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
US$ ६.१३
arrow_upward
+२.८५%(+०.१७) 1D
अक्टोबर ७, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
US$ ५.८५
High
US$ ६.३५
Low
US$ ५.८५
Mkt. cap
२.४८ करोड
Avg. vol.
२६.५२ हजार
Volume
२५.००
P/E ratio
०.१४
52-wk high
US$ ९.७०
52-wk low
US$ ५.६२
EPS
US$ ४५.३०
Beta
१.०५
Shares outstanding
४०.४९ लाख
No. of employees
३४
Open
US$ ५.८५
High
US$ ६.३५
Low
US$ ५.८५
Mkt. cap
२.४८ करोड
Avg. vol.
२६.५२ हजार
Volume
२५.००
P/E ratio
०.१४
52-wk high
US$ ९.७०
52-wk low
US$ ५.६२
EPS
US$ ४५.३०
Beta
१.०५
Shares outstanding
४०.४९ लाख
No. of employees
३४
News stories
From web sources and news partners
AD HOC NEWS
·
३ घण्टा पहिले
Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs EUR 5.45
Investing.com Canada
·
१ दिन पहिले
Form 4 Kyntra Bio Inc For: 6 October By Investing.com
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees३४
Founded१९९३ जनवरी १
Headquartersसान फ्रान्सिस्को, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitekyntrabio.com